AzTrials
AzTrials

Dental DiseaseNCT02814799

Effects of the Bone Tissue on the Haemostasis

An observational study of Dental Disease, run by CHU de Reims at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The research for a haemostasis and for an effective osseous healing are a major stake in oral surgery. The use of glues of fibrin, amplifying the polymerization of the fibrin during the haemostasis is known to reduce the risk of post-operative bruise and accelerate the healing but these glues present the inconvenience… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Dental Disease
What is being tested?
bone removal
How many people
30 participants
Where
1 siteFrance
Study dates
May 2013to Dec 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The inclusive patients will be all the patients requiring dental extractions with bone removal, taken care in the department of odontology of the CHU of Reims and agreeing to participate in the study. Only these patients form the group of observed patients. The duration of participation of the patient in the study is punctual, the time of the osseous taking.

Inclusions criteria

Will be included in this study:

  • The patients requiring dental extractions with bone removal
  • The patients agreeing to participate in the search

Exclusions criteria

Will not be included in this study:

  • Minor patients.
  • Patients protected by the law.

Trial locations and contacts

1 site in 1 country.

Sébastien LAURENCE contact

sebastien.laurence@univ-reims.fr

France1 site, 1 recruiting
  • Chu Reims

    France, Reims, 51092

    Damien JOLLY, 326788472 ext. 33, djolly@chu-reims.fr

    Recruiting

Other trials in France

About this study

Official title: Study of the Effects of the Bone Tissue on the Generation of Thrombine

The research for a haemostasis and for an effective osseous healing are a major stake in oral surgery. The use of glues of fibrin, amplifying the polymerization of the fibrin during the haemostasis is known to reduce the risk of post-operative bruise and accelerate the healing but these glues present the inconvenience to be by-products of the blood, not devoid of infectious risk.

Read the detailed description

Thrombinography is a functional exploration of the haemostasis allowing the characterization of the kinetics and the amount of thrombin. Its principle bases on the recording of the activity of the in vitro thrombin, by fluorometry. The formed thrombin leads a signal by activation of the fluorogenic substrates. The intensity of the received signal is correlated in the generation of thrombin by comparative measure of the fluorescence of a standard sample of thrombinic activity known. The analysis is realized by a specific software: Thrombinoscope®. The used reactional environment is a poor Plasma in platelet (PPP).

The software defines the quantity of thrombin generated (nM) according to time (in minute) and calculate the values of:

  • Lag time: latent period before the beginning of synthesis of thrombin.
  • Start Tail: duration of the process.
  • Peak: peak of thrombin, is the maximal rate of generated thrombin.
  • ETP (Endogenous Thrombin Potential): area under the curve representing the total potential of generation of thrombin.
  • Time to Peak: time required to reach the peak of thrombin. It is these values which will serve as criteria of evaluation for our study.

Osseous type

The cancellous bone is majority in the short bones and the epiphyses of the long bones. It is crisp, constituted by fine osseous patches arranged in a not concentric way around wide open cavities, filled with bone marrow rich in cells, and richly vascularized. The cancellous bone is surrounded with compact bone. At the level of tooth sockets, this osseous type is found in particular at the level of interradicular septa.

The compact bone establishes the cortical. It is dense, consisted of systems of Havers. Every system is formed by a reduced central channel containing some vascularized connective tissue, and thick, concentric osseous small strips, in and between which prepares ostéocytes. This osseous type is situated at the alveolar level in the external part.

Inhibitors

To verify the possible ways involved in the thrombin formation, the investigators shall use specific inhibitors of these likely ways of activation:

  • An inhibitor of the extrinsic way of the coagulation: an antibody anti tissue factor.
  • An inhibitor of the intrinsic way of the coagulation: the bovine aprotinin.
  • An inhibitor of phospholipids: the annexin V. Methodology of the Research

Plan of investigation

  • Information of the eligible patients for the study (patients requiring dental extractions with bone removal) concerning the methods and the objectives of the research by means of the information note.
  • If the patient agrees to participate in the study, realization of osseous takings and conditioning of the osseous takings for freezing in the liquid nitrogen.
  • Put in touch by the osseous takings with some plasma (from pools of plasma used in laboratory for the calibration of the various automatous) and measure of the genesis of thrombin by thrombinography.

To make this measure, the osseous fragments will be put down at the bottom of the wells of the microplate then 10µL of buffer HBS will be added. The fragmentation of the osseous takings will be realized by means of a sterile material and by limiting the time of manipulation except environment.

Every sample will be handled triplicate there. Two wells will be dedicated to the standard thrombin (20µL). Two controls will be used: - positive control: 10µL of tissue factor, in the concentration of 1 or 5 pM and 10µL of PPL in the dilution of 1/100 will be used.

  • Negative control: 20µL of physiological salt solution will be used. Eighty microliters of plasma are going to be put down in each of the wells. Fifty microliters of fluorescent substratum will be added to the mixture buffer - substratum fluorogenic beforehand prepared and the device is going to distribute 20µL some mixture in each of the wells, thus containing in the end 120µL.

The measures were made every 20 seconds during 60 minutes by the Fluoroskan Ascent Reader. The Thrombinoscope softwar® (Version 3.0.0.29, Maastricht) converts the intensity of fluorescence nM of thrombin according to the time.

The results of the measures will be grouped in cancellous bone, compact bone, control FT1pM, control FT5pM and secondarily averaged.

According to the obtained results, samples (compact and\or cancellous) positive for the genesis of thrombin will be analyzed in the presence of specific inhibitors of the various possible ways of activation of the coagulation. Calibrations will be made to choose the most appropriate concentration in inhibitors.

Logistics of the study

An information concerning the objectives and the modalities of the study will be given to every patient benefiting from one or several dental extractions with bone removal. If the patient agrees to participate in the study (oral agreement), the osseous taking, associated automatically with the dental extraction will be kept.

After taking, the osseous fragments will be immersed in a solution of cryopreservation beforehand prepared, then put down in a freezer in -70°C during a minimum of 24 hours before being immersed in the liquid nitrogen.

The measures of trhombinography will be realized at the rate of an analysis every other week, adaptable periodicity according to the number of recruitment made during the period.

Conditions
Dental Disease
Being tested
bone removal
Medical subject headings
Stomatognathic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • bone removalOther

Study groups in NCT02814799
Study groupRoleWhat they receive
bone donorsNot described
Receives: Other: bone removal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. thrombin quantification

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jun 2016 (estimated)
  2. Study startMay 2013
  3. Primary completionDec 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02814799
Sponsor's protocol ID
PJ12077
Status last verified
Jun 2016
First submitted
21 Jun 2016
Last updated
28 Jun 2016
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Dental Disease, run by CHU de Reims at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Sébastien LAURENCE (sebastien.laurence@univ-reims.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

thrombin quantification (time frame: Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in